EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effects of Modified Risk Tobacco Product Claims on Consumer Responses

Andrew B Seidenberg iD, Marcella H Boynton, Noel T Brewer, Allison J Lazard iD, Paschal Sheeran iD, Kurt M Ribisl

Nicotine and Tobacco Research · 22.03.2024 · 26 (4) · 435-443

DOI: 10.1093/ntr/ntad187 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nicotine and Tobacco Research, online erschienen am 04.10.2023. Verfasst von Andrew B Seidenberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Electronic Nicotine Delivery Systems, Tobacco Products. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NCI NIH HHS, FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

US tobacco manufacturers can seek authorization from the US Food and Drug Administration (FDA) to market products using modified risk tobacco product (MRTP) claims. To inform regulatory decisions, we examined the impact of MRTP claim specificity and content, including whether the claims produced halo effects (ie, inferring health benefits beyond what is stated). Aims and Methods Participants were 3161 US adult cigarette smokers. Using a two (general vs. specific) × 2 (risk vs. exposure) plus independent control design, we randomized participants to view one message from these conditions: general risk claim (eg, “smoking-related diseases”), general exposure claim (eg, “chemicals in smoke”), specific risk claim (eg, “lung cancer”), specific exposure claim (eg, “arsenic”), or control. Claims described the benefits of completely switching from cigarettes to the heated tobacco product IQOS.

Results

MRTP claims of any sort elicited a higher willingness to try IQOS relative to control (d = 0.09, p = .043). Claims also elicited lower perceived risk of disease and exposure to harmful chemicals for completely switching from cigarettes to IQOS (d = –0.32 and –0.31) and partially switching (d = –0.25 and d = –0.26; all p < .05). Relative to specific MRTP claims, general MRTP claims led to lower perceived risk and exposure for complete switching (d = –0.13 and d = –0.16) and partial switching (d = –0.14 and d = −0.12; all p < .05). Risk and exposure MRTP claims had similar effects (all p > .05).

Discussion

MRTP claims led to lower perceived risk and exposure, and higher willingness to try IQOS. General claims elicited larger effects than specific claims. MRTP claims also promoted unintended halo effects (eg, lower perceived risk of disease and chemical exposure for partial switching).

Implications

We found evidence that MRTP claims promoted health halo effects. In light of these findings, the FDA should require research on halo effects prior to authorization. Further, if an MRTP claim is authorized, FDA should require tobacco manufacturers to conduct post-market surveillance of how the claim affects consumer understanding, including partial switching perceived risk and exposure beliefs, as well as monitoring of dual-use behaviors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Electronic Nicotine Delivery SystemsTobacco ProductsAdultHumansSmokersSmokingTobacco Smoking

Autor:innen und Institutionen

  • Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Schroeder Institute, Truth Initiative, Washington, DC, USA.
  • Division of General Medicine and Clinical Epidemiology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Hussman School of Journalism and Media, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

ORCID-Profile: Andrew B Seidenberg, Allison J Lazard, Paschal Sheeran

Förderung

  • NIDA NIH HHS
  • NCI NIH HHS
  • FDA HHS
  • Center for Tobacco Products
  • National Cancer Institute
  • Food and Drug Administration

Zitieren

APA

Seidenberg, A. B., Boynton, M. H., Brewer, N. T., Lazard, A. J., Sheeran, P., & Ribisl, K. M. (2024). Effects of Modified Risk Tobacco Product Claims on Consumer Responses. Nicotine and Tobacco Research, 26(4), 435-443. https://doi.org/10.1093/ntr/ntad187

Vancouver

Seidenberg AB, Boynton MH, Brewer NT, Lazard AJ, Sheeran P, Ribisl KM. Effects of Modified Risk Tobacco Product Claims on Consumer Responses. Nicotine and Tobacco Research. 2024;26(4):435-443. doi:10.1093/ntr/ntad187

BibTeX
@article{Seidenberg2024,
  author = {Seidenberg, Andrew B and Boynton, Marcella H and Brewer, Noel T and Lazard, Allison J and Sheeran, Paschal and Ribisl, Kurt M},
  title = {Effects of Modified Risk Tobacco Product Claims on Consumer Responses},
  journal = {Nicotine and Tobacco Research},
  year = {2024},
  volume = {26},
  number = {4},
  pages = {435--443},
  doi = {10.1093/ntr/ntad187}
}
Kostenlos starten →